← All trials
NCT04790786
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Dec 31, 2022
- First posted
- Mar 10, 2021
- Last posted
- Jul 20, 2021
- Enrollment
- 5000
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghSponsor investigator
- University of PittsburghStudy director
- University of PittsburghOverall official - principal investigator
- Berry ConsultantsCollaborator
- University of PittsburghCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.